Physician profile
Avery Ann Lebowitz
NPI 1619675790
$4,059.06
in general payments reported to CMS, 2019-2025
15 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $649 · 2024: $1,745 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.07 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $883.09 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $826.94 | 2023-2025 | |
| Gilead Sciences, INC. | $440.44 | 2024-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $439.82 | 2024-2025 | Rezdiffra |
| Genzyme Corporation | $319.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $270.22 | 2024-2025 | Entyvio |
| Ardelyx, INC. | $232.57 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $165.27 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $164.78 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $138.51 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $55.27 | 2025 | Iqirvo |
| Qol Medical, LLC | $42.71 | 2024 | Sucraid |
| Pfizer INC. | $41.66 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $20.43 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.07 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Lebowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.